The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trialdoi:10.1038/s41591-023-02593-0Tebotelimab, a bispecific PD-1脳LAG-3 DART molecule that blocks both PD-1 and LAG-3, was investigated for clinical safety and activity in ...